What Is IBS-D? Symptoms, Causes, and Treatment

IBS-D, or irritable bowel syndrome with diarrhea, is the most common subtype of IBS, a condition that accounts for a large share of all gastroenterology referrals worldwide. It is defined by recurring abdominal pain linked to loose or watery stools, and the “D” simply distinguishes it from subtypes dominated by constipation (IBS-C) or a mix of both (IBS-M). While the name suggests a single disease, IBS-D turns out to involve several overlapping mechanisms, from disrupted gut-brain signaling and bile acid imbalances to shifts in the intestinal microbiome, which makes both diagnosis and treatment more layered than most people expect.

How IBS-D Is Defined and Diagnosed

The standard diagnostic framework for IBS is the Rome IV criteria, which require recurrent abdominal pain at least one day per week on average over the preceding three months, with that pain connected to defecation, a change in stool frequency, or a change in stool form. Without abdominal pain, the diagnosis does not apply; someone who has frequent loose stools but no pain would more likely be classified as having functional diarrhea, which is a separate condition.¹ For IBS-D specifically, the patient’s abnormal stools are predominantly loose or watery, typically rating 6 or 7 on the Bristol Stool Form Scale, on at least a quarter of bowel movements.

There is no blood test or imaging study that confirms IBS-D. Diagnosis is made by matching symptoms to the Rome IV criteria and ruling out red flags such as unexplained weight loss, blood in the stool, anemia, or a family history of colorectal cancer or inflammatory bowel disease. A doctor will usually take a detailed history covering diet, medications, prior surgeries, and psychological health before making the call. This symptom-based approach works well in most cases, but it also means that conditions mimicking IBS-D can slip through, a problem worth its own discussion below.

What the Symptoms Actually Feel Like

The hallmark of IBS-D is cramping abdominal pain that comes in waves, often relieved (at least temporarily) by a bowel movement. The diarrhea itself tends to cluster in the morning or after meals, sometimes with an urgency so intense that people plan their lives around bathroom access. Mucus in the stool is common and does not signal anything more serious on its own, though it understandably alarms people who notice it. Bloating and excessive gas frequently tag along, and many people describe a sensation of incomplete evacuation even after multiple trips to the bathroom.

Beyond the gut, IBS-D often comes with fatigue, brain fog, and disrupted sleep. Anxiety and depression scores are consistently higher in people with IBS-D compared to healthy controls, with one study finding that patients reported roughly three times the anxiety and depression symptom severity of matched controls.² That psychological burden is not merely a side effect of having a chronic illness; it feeds back into gut function through the gut-brain axis, creating a cycle that amplifies both the emotional and physical symptoms.

Visceral Hypersensitivity and Colonic Motility

One of the core features of IBS-D is visceral hypersensitivity, meaning the gut’s nerves react to stretching and pressure at thresholds much lower than normal. When researchers inflate a small balloon inside the colon, people with IBS-D report their first sensation of discomfort at roughly 31 mL of inflation compared to about 52 mL in healthy volunteers, and their maximum tolerable level is nearly half that of controls.² In practical terms, normal amounts of gas or stool moving through the colon create pain signals that a healthy gut would ignore.

On top of that heightened sensitivity, the colon itself contracts more forcefully and more often. High-amplitude propagating contractions, the powerful squeezing waves that push stool rapidly forward, are more frequent and stronger in IBS-D patients than in controls, and abdominal pain coincides with more than 90 percent of those contractions.³ Faster transit means less time for the colon to absorb water from stool, which explains the loose consistency. Pain and diarrhea in IBS-D are not separate problems; they are two consequences of the same underlying neuromuscular hyperactivity.

The Leaky Gut Connection

A majority of people with IBS-D show increased intestinal permeability, sometimes called “leaky gut.” A systematic review found that somewhere between 37 and 62 percent of IBS-D patients had measurable barrier dysfunction, compared to only 4 to 25 percent of those with the constipation-predominant subtype.⁴ The leakiness is localized mostly to the colon, and it correlates with stool frequency: the more permeable the lining, the more often a person tends to go.⁵

What causes the barrier to weaken is still being studied. The tight junctions between cells in the gut lining appear to be disrupted in a subset of patients, possibly driven by low-grade inflammation, stress hormones, or shifts in the microbiome.⁶ When the barrier weakens, molecules from the gut lumen can interact more freely with immune cells in the intestinal wall, potentially triggering the kind of low-grade inflammation found in many IBS-D patients. This does not rise to the level of visible damage you would see in inflammatory bowel disease, but it appears to be enough to sensitize nerves and drive symptoms.

Bile Acid Problems in IBS-D

One of the more underappreciated drivers of IBS-D involves bile acids, the digestive molecules your liver makes to help absorb fats. Normally, bile acids are recycled efficiently through the small intestine and sent back to the liver. When that recycling system malfunctions, excess bile acids spill into the colon, where they stimulate water secretion and speed up contractions, producing urgent, watery diarrhea. Roughly a quarter to half of people diagnosed with IBS-D have evidence of this bile acid malabsorption.⁷

Research has confirmed that patients with IBS-D have significantly elevated levels of primary bile acids in their stool, and that the frequency of bowel movements tracks with those levels.⁸ The same study found that certain gut bacteria families, particularly Ruminococcaceae, were depleted in IBS-D patients. Those bacteria normally convert primary bile acids into secondary bile acids, which are less irritating to the colon. When the bacteria are missing, the primary acids accumulate and provoke symptoms. This is an area where the gut microbiome and bile acid metabolism intersect in a way that may eventually open up targeted treatments.

Genes also play a role. Variants in genes involved in bile acid synthesis and its feedback regulation (such as KLB and FGFR4) have been linked to colonic transit speed in IBS-D, suggesting that some people are genetically primed to produce or excrete too much bile acid.⁹

Post-Infectious IBS-D

A significant number of IBS-D cases begin after a bout of food poisoning or gastroenteritis, a pattern known as post-infectious IBS. The acute infection clears, but the gut never quite resets. Lingering low-grade inflammation, increased intestinal permeability, and alterations in gut bacteria all persist, sometimes for years.¹⁰ Research following patients after Campylobacter infections found elevated serotonin-producing cells and increased immune cells in gut tissue that could persist for up to four years, with each standard deviation rise in those serotonin-producing cells roughly quadrupling the risk of developing post-infectious IBS.¹¹

If you can pinpoint the onset of your symptoms to a specific infection, your doctor may be more confident in the IBS-D diagnosis and less likely to pursue an exhaustive workup for other causes. Post-infectious IBS also tends to carry a slightly better prognosis over time, as the inflammatory changes gradually fade in some patients.

Conditions That Mimic IBS-D

Because IBS-D is diagnosed by symptoms, a number of other conditions can look nearly identical. A recent narrative review catalogued the most common mimics, including microscopic colitis, bile acid diarrhea, celiac disease, small intestinal bacterial overgrowth (SIBO), exocrine pancreatic insufficiency, lactose and sucrose enzyme deficiencies, early inflammatory bowel disease, and thyroid disorders.¹² All of these can produce abdominal pain and loose stools, and each has its own targeted treatment that would be missed if the patient is simply managed as IBS-D.

SIBO deserves special mention because it overlaps with IBS-D so often that the two conditions sometimes coexist. Estimates of how many IBS patients also have SIBO vary wildly, from under 5 percent to over 75 percent, depending on how SIBO is tested and which diagnostic criteria are used.¹³ SIBO can worsen IBS-D symptoms by adding its own bacterial fermentation and gas production on top of the existing motility problems. It is also worth noting that IBS and inflammatory bowel disease, while clearly different conditions, share features at a microscopic level, including immune activation, altered permeability, and microbiome disruption. About one in three IBD patients in remission from active inflammation still experience IBS-like symptoms.¹⁴

Dietary Approaches

The low-FODMAP diet is the most studied dietary intervention for IBS-D. FODMAPs are short-chain carbohydrates found in foods like wheat, onions, garlic, beans, certain fruits, and artificial sweeteners that are poorly absorbed in the small intestine and rapidly fermented by gut bacteria, producing gas and drawing water into the bowel. A randomized crossover trial found that a low-FODMAP diet reduced overall symptom severity, pain intensity, and stool frequency compared to a moderate-FODMAP diet, with stools becoming firmer during the low-FODMAP phase. About a third of participants met the threshold for a clinical response.¹⁵

A separate randomized trial comparing the low-FODMAP diet to standard dietary advice in people specifically diagnosed with IBS-D found that about half of the low-FODMAP group reported adequate symptom relief, and the diet was particularly effective for abdominal pain, with roughly twice as many responders compared to standard advice.¹⁶ The diet is typically done in three phases: a strict elimination period, a structured reintroduction phase where you test individual FODMAP groups, and a long-term personalization phase. Working with a dietitian helps, since the elimination phase is restrictive enough that doing it indefinitely could lead to nutritional gaps and an unnecessarily narrow diet.

Medications for IBS-D

Several prescription medications target different aspects of IBS-D, and a network meta-analysis of 18 randomized trials covering nearly 10,000 patients found that all four major drug classes studied were superior to placebo for the combined endpoint of improved pain and stool consistency at 12 weeks.¹⁷ Here is how the main options stack up:

• 5-HT3 receptor antagonists (alosetron, ramosetron): These slow gut motility and reduce visceral sensitivity by blocking serotonin receptors in the gut. Alosetron was ranked the most effective overall in that meta-analysis, and ramosetron ranked first for pain relief. However, both carry a higher rate of side effects, particularly constipation, and alosetron is restricted in the U.S. to women with severe IBS-D who have not responded to other treatments, owing to rare but serious cases of reduced blood flow to the colon.
• Rifaximin: A gut-targeted antibiotic that is minimally absorbed into the bloodstream. Two large trials found that about 41 percent of patients treated with rifaximin reported adequate symptom relief, compared to roughly 32 percent on placebo, with similar improvements in bloating and stool consistency.¹⁸ Rifaximin ranked first for safety among the drugs studied, with constipation rates no higher than placebo. It is typically given as a two-week course that can be repeated if symptoms return.
• Eluxadoline: This medication acts on opioid receptors in the gut wall to slow motility and reduce pain signaling without the systemic effects of traditional opioids. In two phase 3 trials, the 100 mg dose produced sustained improvement over six months, with response rates roughly double those of placebo during the first 12 weeks.¹⁹ It is not suitable for people without a gallbladder or those who drink heavily, because of a small risk of pancreatitis.
• Bile acid sequestrants (cholestyramine, colesevelam): These bind excess bile acids in the gut and are used off-label for people whose IBS-D is driven by bile acid malabsorption. One trial found that colesevelam reduced stool consistency scores on the Bristol scale and showed an inverse relationship between bile acid sequestration and bowel movements, meaning the more drug bound the bile acids, the less diarrhea occurred.²⁰ However, a separate randomized trial found no significant group-level difference in stool frequency or consistency between colesevelam and placebo, even in the subgroup with elevated markers of bile acid production.²¹ The mixed evidence suggests bile acid binders help some patients meaningfully, but predicting who will respond remains a challenge.

Over-the-counter options like loperamide (the active ingredient in Imodium) are widely used for urgent symptom control. It slows gut motility and reduces fluid secretion, but it does not address the underlying pain. Many gastroenterologists recommend it as a rescue medication for specific situations rather than a daily regimen.

Brain-Gut Therapies

Because IBS-D involves disordered communication between the brain and the gut, psychological therapies can produce real, measurable changes in bowel symptoms, not just mood. Cognitive behavioral therapy (CBT) and gut-directed hypnotherapy have the strongest evidence among these approaches, and both are now recommended as second-line treatments by European and North American gastroenterology guidelines.²²

CBT for IBS focuses on breaking the cycle where catastrophic thinking about symptoms (“What if I can’t find a bathroom?”) amplifies the brain’s pain signals to the gut, which in turn worsens diarrhea and urgency, which reinforces the fear. Gut-directed hypnotherapy uses guided relaxation and positive suggestion to reduce visceral sensitivity directly. Both approaches have shown long-term durability, with benefits that persist well beyond the treatment period.²³ Access can be a barrier, but app-based CBT programs designed specifically for IBS have emerged in recent years and are beginning to accumulate evidence of their own.

Probiotics

The evidence on probiotics for IBS-D is more encouraging than for IBS in general, largely because specific strains have shown targeted effects on stool frequency and consistency. A network meta-analysis found that several probiotic strains were significantly better than placebo at reducing bowel movement frequency in IBS-D, with Bacillus coagulans MTCC 5856 and Saccharomyces cerevisiae CNCM I-3856 ranking among the most effective for improving stool form.²⁴ A randomized placebo-controlled trial of a multi-strain formulation in IBS-D patients found a 69 percent reduction in abdominal pain severity with the probiotic compared to 47 percent with placebo, along with a significant drop in daily bowel movements starting from the second month of treatment.²⁵

The catch is that strain specificity matters enormously. A probiotic that works for bloating may do nothing for diarrhea, and one formulation’s results cannot be generalized to another just because both are labeled “probiotics.” If you want to try one, look for products that name the specific strain (not just the species) and that have been tested in IBS-D populations.

Who Gets IBS-D

IBS as a whole is more common in women, who are roughly twice as likely to be affected as men in Western populations.²⁶ Within IBS subtypes, the gender split is less even: women are disproportionately represented in IBS-C, while IBS-D has a somewhat more balanced sex ratio. Ovarian hormones appear to modulate gut motility, pain processing, and stress reactivity, which may explain why many women with IBS-D notice symptom fluctuations across their menstrual cycle.²⁷ Women with IBS-D also tend to report higher levels of fatigue, depression, and anxiety compared to men with the same diagnosis.

Genetically, IBS-D has been linked to variants in serotonin receptor genes, particularly a polymorphism on the HTR3E gene that was replicated across two separate cohorts.²⁸ A variant near the NXPH1 gene, which is involved in neuronal signaling, has also been associated specifically with IBS-D and survived statistical correction for multiple testing.²⁹ None of these genetic findings are strong enough individually to serve as diagnostic markers, but they reinforce the idea that IBS-D has a biological basis rooted in how the nervous system and immune system interact with the gut.

The Toll on Daily Life

The impact of IBS-D goes well beyond the bathroom. Compared to matched controls, people with IBS-D report significantly lower quality of life on both mental and physical health measures, along with roughly 50 percent more missed workdays and nearly double the rate of reduced productivity while at work.³⁰ Urgency and the unpredictability of symptoms are particularly damaging. In one study, the degree of defecation urgency was an independent predictor of reduced quality of life, more so than pain frequency alone.³¹ Female patients tended to score worse on anxiety and depression scales, which in turn further lowered their quality-of-life ratings.

People often underestimate this burden because IBS-D is not visible and carries no threat of the serious complications associated with inflammatory bowel disease. But the day-to-day reality of planning every outing around restroom access, avoiding travel or social situations, and managing the anxiety that feeds back into symptoms creates a significant and measurable disability that warrants aggressive treatment rather than dismissal.

Sleep Disruption and Circadian Rhythms

Poor sleep is both a trigger and a consequence of IBS-D. Sleep deficiency, including poor quality and inadequate duration, is a modifiable risk factor for symptom flares.³² Animal research has added mechanistic detail: mice subjected to repeated shifts in their light-dark cycle, mimicking the circadian disruption of shift work or chronic jet lag, developed visceral hypersensitivity and increased colonic permeability, two of the hallmark features of IBS-D.³³ The disrupted mice also showed altered fecal metabolites, suggesting that circadian misalignment can reshape the gut’s chemical environment in ways that promote IBS-like symptoms.

For people with IBS-D who work nights, travel frequently across time zones, or simply keep irregular sleep schedules, stabilizing sleep timing may be one of the more accessible interventions available. It will not cure IBS-D on its own, but reducing circadian disruption removes a compounding factor that worsens the same biological pathways already driving the condition.